The Bull Rankings scorecard — our quality-growth score is 72 / 100, built from three pillars scored 0–100: Quality 66, Growth 100, Value 59 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 44% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Caris Life Sciences is a growth‑oriented AI‑driven biotech that just posted a 97% YoY revenue jump and a 10.6% profit margin. Those two figures alone justify a bullish stance, but the real engine is the growth pillar of our model, which scores a perfect 100. The company’s P/E of 17.6 places it in the 25th percentile of Healthcare peers, confirming that the market still sees room for upside. In short, the price is cheap relative to peers, the business is scaling explosively, and the valuation is not yet fully stretched.
What the business actually is
Caris sells molecular profiling services that turn tumor samples into actionable data. Its flagship MI Profile Platform delivers whole‑exome and whole‑transcriptome sequencing for tissue, while the Caris Assure Platform offers the same depth for blood. The Precision Whole Genome Platform expands to whole‑genome sequencing for both blood and tissue, and Caris Detect rounds out the portfolio. These services feed oncologists and pharma partners who need precise, AI‑enhanced insights to guide therapy. The tissue‑based solutions, especially MI Profile, are the current revenue engine, driving the bulk of the 97% growth.
Why it can (or can't) keep compounding
Margins sit at 10.6%, and free cash flow is $124 m for the trailing twelve months. With a debt‑to‑equity of 0.76, the company is not overleveraged. The ROE of 20.1% shows that capital is being deployed efficiently. The moat is algorithmic and data‑centric: the AI models that interpret sequencing data are proprietary and improve with every new sample. Competitors would need to replicate both the sequencing infrastructure and the machine‑learning pipeline, a time‑consuming, capital‑intensive endeavor. Our model’s strongest signal—Growth 100—underscores that the business is already on a trajectory that competitors cannot easily duplicate.
The valuation question
The reverse‑DCF tells us that the current price implies a free‑cash‑flow growth of about 44% in year 1 that tapers to 4% by year 10. That starting rate is lower than the 97% revenue growth just reported. In other words, the market is already pricing in a pessimistic view of future acceleration. The P/E of 17.6, cheaper than most Healthcare peers, suggests that the market still believes the company can sustain high growth, but the implied 44% FCF growth is a conservative anchor. If Caris can maintain or exceed the 97% revenue expansion for a few more quarters, the price would be undervalued relative to the model’s assumptions.
The bear case
The most glaring risk is the short track record signal. Caris has only a few years of operating history, and its PEG ratio of 0.1—while attractive—does not compensate for the lack of long‑term data. A single quarter of revenue decline or a margin squeeze would immediately erode the 97% growth narrative. The company’s value pillar of 59 indicates that, compared to peers, it is already on the cheaper side; any further discounting would be a red flag. If the next earnings cycle shows a drop in revenue growth below 50%, the model would flag a significant deviation from the optimistic trajectory.
What would change our mind
- Revenue growth slips below 70% YoY for two consecutive quarters—this would undermine the Growth 100 score and trigger a reassessment of the reverse‑DCF assumptions.
- Profit margin falls below 8%—a contraction would erode the 10.6% margin that currently supports the 20.1% ROE and free‑cash‑flow generation.
- Debt‑to‑equity rises above 1.0—an increase would signal financial strain and potentially limit the company’s ability to invest in AI and sequencing infrastructure, weakening the moat.
If any of these thresholds are breached, the current thesis would need to be revisited.